Novavax to Participate in Jefferies London Healthcare Conference

On November 11, 2026 Novavax, Inc. (Nasdaq: NVAX) reported that company management will participate in the following upcoming investor conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies London Healthcare Conference, London, United Kingdom
Fireside chat on Tuesday, November 17, 2026, at 5:00 p.m. GMT

A live webcast of the fireside chat will be available on the "Events & Presentations" page of the Company’s website at ir.novavax.com. A replay of each webcast will be available for 30 days following the presentation.

(Press release, Novavax, NOV 11, 2026, View Source [SID1234674614])

Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

On November 11, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, reported the grant of a new patent (number 12,788,796) entitled "Combined Preparations for the Treatment of Cancer or Infection" by the United States Patent and Trademark Office (USPTO).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded progressively through a series of patents granted in December 2020, March 2021, June 2023, July 2026 and, most recently, this latest patent.

The claims of the new patent build on the protection provided by the four previously granted patents and are directed to combined preparations and pharmaceutical compositions comprising eftilagimod alfa ("efti") and a PD-1 pathway inhibitor. Specifically, the claims encompass combinations with BMS-936559, durvalumab, atezolizumab and avelumab. The expiry date of the patent is 23 March 2038 (including 806 days of patent term adjustment).

The patent grant provides additional protection for the use of efti in combination with PD-1 pathway inhibitors, a key class of immunotherapies used in modern cancer treatment, further expanding Immutep’s patent portfolio covering efti-based combination therapies. Immutep has also filed a continuation application to pursue additional embodiments of the invention.

Marc Voigt, CEO of Immutep, said: "We are pleased to receive this latest US patent grant, which further strengthens the intellectual property protection surrounding efti. As we pursue our focused development strategy for efti, a good patent portfolio remains an important strategic asset, supporting future development and partnering opportunities. We believe in the potential of this unique biomolecule and that carefully selected clinical settings could provide meaningful opportunities for continued evaluation and value creation."

About Eftilagimod Alfa (Efti)
Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

(Press release, Immutep, NOV 11, 2026, View Source [SID1234674630])

Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

On November 11, 2026 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported that Leonard Mazur, Chairman and Chief Executive Officer, will participate in the Jefferies London Healthcare Conference, taking place November 16–19, 2026, in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Mazur will provide an overview of the Company’s business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by the Company’s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

Conference Details:

Conference: Jefferies London Healthcare Conference
Dates: November 16–19, 2026
Location: Waldorf Hilton & ME Hotels, London, United Kingdom
Format: one-on-one meetings
One-on-one meetings with management may be scheduled by contacting a conference representative or the Company’s investor relations team.

(Press release, Citius Pharmaceuticals, NOV 11, 2026, View Source [SID1234674615])

Arvinas to Present at Jefferies Global Healthcare Conference

On November 11, 2026 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 18 at 9:00 a.m. GMT/4:00 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company’s website.

(Press release, Arvinas, NOV 11, 2026, View Source [SID1234674631])

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

On November 11, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported members of the senior leadership team will speak at the upcoming Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference, both held in London during Life Sciences Week 2026, November 15-20.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The results from our QUILT-2.005 study bring us closer to our goal of treating bladder cancer earlier in the course of the disease," said Richard Adcock, President and CEO of ImmunityBio. "In London, we look forward to discussing what these findings could mean for patients who have not yet received BCG, our work to expand access to ANKTIVA globally, and where we see the greatest opportunity for our immunotherapy platform."

Presentation Details:
UBS Global Biopharma Conference in London, November 16-17

Date: Monday, November 16
Time: 10:40 – 11:10 GMT
Format: Presentation

To enter the webcast, register at
View Source;tp_key=f6d675b06e&tp_special=8

Jefferies Global Healthcare Conference, November 16-19

Date: Monday, November 16
Time: 12:00 – 12:25 GMT
Format: Fireside chat with Roger Song, MD, CFA, Senior Equity Research Analyst, Jefferies – Research

To view the fireside chat, register at
https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/WnAidpbwHpuLmoRPBWrpPW

Launched by the UK BioIndustry Association, MedCity and London & Partners, London Life Sciences Week is a premier gathering of global investors and leaders from pharma and UK biotech companies, offering a dynamic week of networking and dealmaking.

About ANKTIVA (nogapendekin alfa inbakicept-pmln)

The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells, NK and CD8+ killer T cells, that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 independent of dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.

IMPORTANT U.S. SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with BCG-unresponsive NMIBC have evidence of high-grade disease after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.

USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, and pyrexia. For more information, please see the Prescribing Information for ANKTIVA at Anktiva.com.

(Press release, ImmunityBio, NOV 11, 2026, View Source [SID1234674559])